Price (delayed)
$6.575
Market cap
$391.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.79
Enterprise value
$414.2M
MeiraGTx is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in
There are no recent dividends present for MGTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.